Vcare PharmaTech’s Eratrectinib Revolutionizes Cancer Treatment in China
June 5, 2026Eratrectinib, a next-generation TRK inhibitor developed by Vcare PharmaTech, has been granted marketing approval in China. The approval signifies a significant advancement in cancer treatment, particularly for patients with advanced…..
Subscribe for Full Access!
Original URL: Click here to visit original article